Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians - Tập 71 Số 3 - Trang 264-279 - 2021
Smita S. Joshi1, Brian D. Badgwell2
1Gastrointestinal Oncology Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York
2Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Tóm tắt

AbstractGastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard‐of‐care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD‐L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein‐Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.

Từ khóa


Tài liệu tham khảo

World Health Organization International Agency for Research on Cancer.GLOBOCAN 2018: Estimated Cancer Incidence Mortality and Prevalence Worldwide. Accessed June 16 2020.globocan.iarc.fr

The American Cancer Society.Cancer Statistics Center. Accessed June 16 2020.cancerstatisticscenter.cancer.org

10.1146/annurev-med-081117-043436

10.1097/SLA.0000000000001793

10.1097/SLA.0b013e3181d3d29b

10.1002/1097-0142(20001201)89:11<2237::AID-CNCR12>3.0.CO;2-9

10.6004/jnccn.2016.0139

10.1186/s13045-017-0517-9

10.1136/gutjnl-2014-308252

American Institute for Cancer Research World Cancer Research Fund.Stomach Cancer. How Diet Nutrition and Physical Activity Affect Stomach Cancer Risk. Accessed November 24 2020.www.wcrf.org/dietandcancer/stomach‐cancer

10.1001/jamaoncol.2014.168

10.1016/S2468-1253(18)30237-1

10.3748/wjg.14.1149

10.21037/jgo.2017.04.04

10.1007/s00595-020-02018-2

10.1245/s10434-016-5409-7

National Comprehensive Cancer Network (NCCN).NCCN Guidelines Version 2.2020. Gastric Cancer. Accessed June 15 2020.www.nccn.org

10.1002/jso.25094

10.1200/JCO.19.01124

10.1001/jamaoncol.2016.6762

10.1097/SLA.0000000000002803

10.1002/cncr.31155

10.1056/NEJMoa055531

10.1200/JCO.2016.69.7276

10.1200/JCO.2010.33.0597

10.1016/S0140-6736(18)32557-1

10.1200/JCO.2020.38.15_suppl.4502

10.1200/JCO.2020.38.15_suppl.4501

10.1016/S0140-6736(11)61873-4

10.1200/JCO.2011.36.5908

10.1200/JCO.18.01138

10.1056/NEJMoa010187

10.1200/JCO.2011.39.1953

10.1200/JCO.2019.37.15_suppl.4001

10.1007/s00432-011-1085-y

10.1016/j.jamcollsurg.2015.04.004

10.1056/NEJMoa1112088

10.1200/JCO.2005.01.305

10.1200/JCO.2004.01.015

10.1200/JCO.2006.06.4840

Allen CJ, 2020, Chemotherapy versus chemotherapy plus chemoradiation as preoperative therapy for resectable gastric adenocarcinoma: a propensity score‐matched analysis of a large, single‐institution experience, Ann Surg Oncol

10.1245/s10434-016-5645-x

10.1007/s10120-016-0622-4

10.1056/NEJMoa073149

10.1016/j.ejca.2012.09.025

10.1016/j.ejca.2012.12.016

10.1016/S0140-6736(13)61719-5

10.1016/S1470-2045(14)70420-6

10.1016/S1470-2045(18)30739-3

10.1038/nature13480

10.1158/2159-8290.CD-17-0787

10.1056/NEJMoa1500596

10.1200/JCO.19.02105

US Food and Drug Administration [FDA], 2017, FDA approves first cancer treatment for any solid tumor with a specific genetic feature

10.1200/JCO.2020.38.4_suppl.430

10.1200/JCO.2020.38.15_suppl.4503

10.1001/jamaoncol.2020.3370

Boku N, 2017, 617OA Phase 3 study of nivolumab (Nivo) in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: updated results and subset analysis by PD‐L1 expression (ATTRACTION‐02), Ann Oncol, 28, mdx369.001

10.1200/JCO.2017.76.6212

Moehler MH, 2018, CheckMate 649: a randomized, multicenter, open‐label, phase III study of nivolumab (NIVO) + ipilimumab (IPI) or nivo + chemotherapy (CTX) versus CTX alone in patients with previously untreated advanced (Adv) gastric (G) or gastroesophageal junction (GEJ) cancer [abstract], J Clin Oncol, 36, TPS192, 10.1200/JCO.2018.36.4_suppl.TPS192

10.1016/j.annonc.2020.08.2296

10.1093/annonc/mdy264

10.1016/S1470-2045(20)30445-9

10.1200/JCO.2020.38.15_suppl.4537

10.1158/1078-0432.CCR-18-3603

10.18632/oncotarget.9076

10.1038/s41591-018-0101-z

10.1007/s10120-014-0402-y

10.1016/S0140-6736(10)61121-X

10.1200/JCO.2015.62.6598

10.1200/JCO.2013.53.6136

10.1016/S1470-2045(17)30111-0

10.1016/S1470-2045(18)30481-9

10.1200/JCO.19.03077

10.1200/JCO.2018.36.15_suppl.2500

10.1093/annonc/mdx002

10.1056/NEJMoa2004413

10.1016/S1470-2045(20)30169-8

10.1016/S1470-2045(20)30271-0

10.1200/JCO.19.03296

10.1200/JCO.2010.29.2847

10.1016/S1470-2045(13)70102-5

10.1016/S1470-2045(14)70024-5

10.1158/2159-8290.CD-17-1260

10.1093/annonc/mdz199

Al‐Batran SE, 2016, FAST: an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first‐in‐class anti‐CLDN18.2 antibody, as first‐line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma [abstract], J Clin Oncol, 34, LBA4001, 10.1200/JCO.2016.34.18_suppl.LBA4001

10.1002/cncr.31940

10.1245/s10434-017-5838-y

10.3109/0284186X.2013.850740

10.1245/s10434-011-1631-5

10.1200/JCO.18.01688

10.1007/s00104-018-0645-y

10.1186/s12885-019-5640-2

10.1245/s10434-007-9487-4

10.1007/s10120-016-0684-3

10.1186/1471-2407-14-183

10.1038/s41467-020-14310-3

10.1158/1078-0432.CCR-19-1704

Thông tin
Thông tin xuất bản

Ca-A Cancer Journal for Clinicians

Tập 71 Số 3

264-279

Thông tin tác giả